Anticoagulation With Otamixaban and Ischemic Events in Non-ST-Segment Elevation Acute Coronary Syndromes The TAO Randomized Clinical Trial

Date
2013
Author
Ruiz-Nodar, Juan M.
Hoekstra, James
Rao, Sunil V.
Ruzyllo, Witold
Sabate, Manel
Widimsky, Petr
Kiss, Robert Gabor
Navarro Estrada, Jose Luis
Hod, Hanoch
Kerkar, Prafulla
Guneri, Sema
Ruda, Mikhail
Nicolau, Jose Carlos
Cavallini, Claudio
Ebrahim, Iftikhar
Petrov, Ivo
Kim, Jae-Hyung
Jeong, Myung-Ho
Ramos Lopez, Gabriel Arturo
Laanmets, Peep
Kovar, Frantisek
Gaudin, Christophe
Fanouillere, Karen C.
Minini, Pascal
Hoffman, Elaine B.
Moryusef, Angele
Wiviott, Stephen D.
Sabatine, Marc S.
Sezer, Murat
Steg, Philippe Gabriel
Mehta, Shamir R.
Pollack, Charles V.
Bode, Christoph
Cohen, Marc
French, William J.
Metadata
Show full item record
Abstract
IMPORTANCE The optimal anticoagulant for patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) managed with an invasive strategy remains controversial.
URI
http://hdl.handle.net/20.500.12627/143356
https://doi.org/10.1001/jama.2013.277165
Collections